CEL-SCI appoints Dr. Nabil Saba as lead for Phase III Multikine study in head and neck cancer

CEL SCI CORP

Dr. Saba will serve as global Phase III confirmatory trial lead and Study Steering Committee member for Multikine.
He is a recognized head and neck cancer expert, professor at Emory, and has led over 50 clinical trials.
Appointment positions CEL-SCI for its upcoming confirmatory registration study in newly diagnosed head and neck cancer.
Dr. Saba chairs NCI head and neck cancer task forces and holds NIH funding for related research.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.